Immunotherapies inducing immunogenic cell death in cancer: insight of the innate immune system.
cellular therapies
cytokines
immunogenic cell death
immunomodulators
innate immune system
monoclonal antibodies
onco-immunotherapy
oncolytic virus
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2023
2023
Historique:
received:
14
09
2023
accepted:
01
11
2023
medline:
11
12
2023
pubmed:
11
12
2023
entrez:
11
12
2023
Statut:
epublish
Résumé
Cancer immunotherapies include monoclonal antibodies, cytokines, oncolytic viruses, cellular therapies, and other biological and synthetic immunomodulators. These are traditionally studied for their effect on the immune system's role in eliminating cancer cells. However, some of these therapies have the unique ability to directly induce cytotoxicity in cancer cells by inducing immunogenic cell death (ICD). Unlike general immune stimulation, ICD triggers specific therapy-induced cell death pathways, based on the release of damage-associated molecular patterns (DAMPs) from dying tumour cells. These activate innate pattern recognition receptors (PRRs) and subsequent adaptive immune responses, offering the promise of sustained anticancer drug efficacy and durable antitumour immune memory. Exploring how onco-immunotherapies can trigger ICD, enhances our understanding of their mechanisms and potential for combination strategies. This review explores the complexities of these immunotherapeutic approaches that induce ICD, highlighting their implications for the innate immune system, addressing challenges in cancer treatment, and emphasising the pivotal role of ICD in contemporary cancer research.
Identifiants
pubmed: 38077402
doi: 10.3389/fimmu.2023.1294434
pmc: PMC10701401
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1294434Informations de copyright
Copyright © 2023 Calvillo-Rodríguez, Lorenzo-Anota, Rodríguez-Padilla, Martínez-Torres and Scott-Algara.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.
Références
Lancet. 2000 Nov 25;356(9244):1795-9
pubmed: 11117911
Cancers (Basel). 2023 May 25;15(11):
pubmed: 37296876
Adv Funct Mater. 2020 Mar 17;30(12):
pubmed: 33071706
Leuk Lymphoma. 2013 Nov;54(11):2500-5
pubmed: 23452151
Nat Med. 2016 Jun;22(6):624-31
pubmed: 27135741
J Immunother Cancer. 2021 Dec;9(12):
pubmed: 34887262
Am J Cancer Res. 2018 Aug 01;8(8):1514-1527
pubmed: 30210920
Mol Oncol. 2014 Mar;8(2):297-310
pubmed: 24388357
J Biol Chem. 1994 Nov 25;269(47):29650-7
pubmed: 7525586
J Oncol. 2020 Jun 8;2020:1598503
pubmed: 32587616
Br J Cancer. 2019 Jan;120(1):6-15
pubmed: 30413827
Nat Med. 2007 Jan;13(1):54-61
pubmed: 17187072
Blood. 2005 Jan 1;105(1):266-73
pubmed: 15331446
Mol Ther Oncolytics. 2022 Sep 13;27:3-13
pubmed: 36212775
Front Immunol. 2022 Jun 16;13:915837
pubmed: 35784326
J Invest Dermatol. 2020 Sep;140(9):1771-1783.e6
pubmed: 32035924
Eur J Pharmacol. 2018 Sep 5;834:188-196
pubmed: 30031797
Nat Rev Cancer. 2012 Mar 22;12(4):237-51
pubmed: 22437869
Oncoimmunology. 2022 Apr 4;11(1):2054305
pubmed: 35402082
Front Immunol. 2020 Jul 02;11:1347
pubmed: 32714329
Genomics. 2001 Mar 1;72(2):119-27
pubmed: 11401424
Br J Cancer. 2021 Apr;124(8):1398-1410
pubmed: 33531687
Cancer Res. 2015 Dec 15;75(24):5273-82
pubmed: 26631269
Biochem Biophys Res Commun. 2009 Aug 28;386(3):455-8
pubmed: 19527683
Autophagy. 2013 Sep;9(9):1292-307
pubmed: 23800749
Clin Cancer Res. 2020 May 1;26(9):2216-2230
pubmed: 32019860
Cancer Med. 2018 Jun;7(6):2654-2664
pubmed: 29733528
J Virol. 2021 Jan 13;95(3):
pubmed: 33177208
Blood Cancer J. 2021 Apr 6;11(4):69
pubmed: 33824268
Kaohsiung J Med Sci. 2021 Sep;37(9):749-758
pubmed: 34110692
Cell. 2020 Feb 20;180(4):749-763.e13
pubmed: 32059780
Cell. 2018 Dec 13;175(7):1731-1743.e13
pubmed: 30503213
Front Bioeng Biotechnol. 2022 Jun 22;10:797440
pubmed: 35814023
Gene Ther. 2013 Jan;20(1):7-15
pubmed: 22170342
Int J Dev Biol. 2015;59(1-3):131-40
pubmed: 26374534
Front Immunol. 2017 Aug 18;8:1001
pubmed: 28868054
Front Immunol. 2017 Sep 13;8:1124
pubmed: 28955340
Mol Cancer Ther. 2021 Oct;20(10):1941-1955
pubmed: 34253590
J Immunother. 2017 Feb/Mar;40(2):71-76
pubmed: 28125513
Cancers (Basel). 2020 Apr 23;12(4):
pubmed: 32340275
Mol Ther Methods Clin Dev. 2020 Jan 15;17:349-358
pubmed: 32071927
Acta Pharm Sin B. 2022 Jun;12(6):2740-2750
pubmed: 35755291
Cancer Immunol Res. 2019 Mar;7(3):363-375
pubmed: 30651290
Mol Cancer. 2023 Mar 21;22(1):58
pubmed: 36941614
FEBS J. 2022 Aug;289(15):4398-4415
pubmed: 34174027
J R Soc Interface. 2013 Jul 31;10(87):20130365
pubmed: 23904584
Int J Immunopharmacol. 1999 Jan;21(1):1-14
pubmed: 10411278
Blood. 2007 Jun 1;109(11):4839-45
pubmed: 17299090
Cancer Gene Ther. 2022 Jun;29(6):793-802
pubmed: 34135475
Oncoimmunology. 2015 Jan 09;4(3):e991615
pubmed: 25949912
Immunol Rev. 2017 Nov;280(1):126-148
pubmed: 29027218
J Infect Dis. 2012 Apr 1;205(7):1035-42
pubmed: 22396610
AIDS Res Hum Retroviruses. 1999 Sep 1;15(13):1169-79
pubmed: 10480630
Cell Death Dis. 2020 Nov 26;11(11):1013
pubmed: 33243969
Oncotarget. 2017 Sep 16;8(45):78277-78288
pubmed: 29108228
J Exp Clin Cancer Res. 2022 Jul 15;41(1):222
pubmed: 35836249
Clin Infect Dis. 2014 Jun;58(12):1734-7
pubmed: 24633683
Cancer Discov. 2021 Jun;11(6):1353-1367
pubmed: 33712487
Mol Ther Oncolytics. 2020 Oct 04;20:434-446
pubmed: 33665363
Clin Cancer Res. 2015 Jul 15;21(14):3274-85
pubmed: 25829396
Cancer Gene Ther. 2016 Apr;23(4):107-13
pubmed: 26987291
Front Immunol. 2015 Oct 07;6:516
pubmed: 26500653
BioDrugs. 2019 Oct;33(5):485-501
pubmed: 31321623
Nature. 2023 Apr;616(7956):348-356
pubmed: 37020026
Cell Immunol. 2016 Feb;300:46-53
pubmed: 26702740
Cancer Res. 2017 Oct 1;77(19):5215-5221
pubmed: 28928130
J Virol. 2014 May;88(10):5263-76
pubmed: 24574398
Biotechnol Bioeng. 2021 Oct;118(10):3691-3705
pubmed: 34241908
Cancer Res. 2015 Dec 15;75(24):5260-72
pubmed: 26494122
Biol Blood Marrow Transplant. 2013 Oct;19(10):1416-20
pubmed: 23707853
Cancer Res. 2003 Feb 1;63(3):593-9
pubmed: 12566301
Molecules. 2020 Jun 17;25(12):
pubmed: 32560527
Pharmacol Res. 2023 Jan;187:106556
pubmed: 36403722
Elife. 2018 Jun 04;7:
pubmed: 29862966
Eur J Immunol. 2008 Feb;38(2):437-47
pubmed: 18203135
Curr Cancer Drug Targets. 2011 Mar;11(3):239-53
pubmed: 21247388
Front Immunol. 2023 May 15;14:1188049
pubmed: 37256141
J Transl Med. 2023 Feb 10;21(1):106
pubmed: 36765373
Haematologica. 2020 Dec 30;107(2):437-445
pubmed: 33375774
Trends Pharmacol Sci. 2021 Jan;42(1):45-59
pubmed: 33250273
J Immunol. 2000 Feb 15;164(4):2193-9
pubmed: 10657674
Actas Dermosifiliogr. 2012 Jun;103(5):441-2
pubmed: 22265009
Genes Immun. 2022 Feb;23(1):1-11
pubmed: 35046546
Mol Cancer. 2015 Sep 24;14:174
pubmed: 26403780
J Immunol Res. 2016;2016:4097642
pubmed: 27847830
Front Med (Lausanne). 2022 Dec 23;9:1102550
pubmed: 36619616
Blood Cancer Discov. 2021 Sep;2(5):468-483
pubmed: 34568832
Cancer Res. 2021 Sep 15;81(18):4641-4651
pubmed: 34145037
Annu Rev Immunol. 2013;31:51-72
pubmed: 23157435
Cells. 2022 Nov 29;11(23):
pubmed: 36497086
Cancer Gene Ther. 2022 May;29(5):475-483
pubmed: 34471234
Cell Death Dis. 2013 Dec 12;4:e966
pubmed: 24336086
Nat Biotechnol. 2020 Aug;38(8):947-953
pubmed: 32361713
Nat Med. 2012 Dec;18(12):1827-34
pubmed: 23178246
Curr Opin Immunol. 2015 Apr;33:1-8
pubmed: 25576932
Cell Death Dis. 2016 Mar 10;7:e2134
pubmed: 26962684
Science. 2013 Dec 20;342(6165):1432-3
pubmed: 24357284
Front Oncol. 2014 Apr 10;4:74
pubmed: 24782985
Semin Oncol. 2012 Jun;39(3):276-86
pubmed: 22595050
Haematologica. 2011 Mar;96(3):400-7
pubmed: 21109686
J Hematol Oncol. 2021 Jan 6;14(1):7
pubmed: 33407739
Pharmaceutics. 2020 Mar 12;12(3):
pubmed: 32178288
Cytotherapy. 2006;8(4):408-14
pubmed: 16923617
Front Pharmacol. 2022 Jul 01;13:940567
pubmed: 35847044
J Immunother Cancer. 2021 Dec;9(12):
pubmed: 34916256
Cancers (Basel). 2020 Feb 27;12(3):
pubmed: 32120810
Pharmacol Res. 2020 Sep;159:105017
pubmed: 32561479
Cell Death Dis. 2020 Jan 22;11(1):48
pubmed: 31969562
PLoS Med. 2015 Mar 03;12(3):e1001796
pubmed: 25734483
Cell Mol Immunol. 2020 Aug;17(8):807-821
pubmed: 32612154
Oncol Lett. 2017 Jul;14(1):844-852
pubmed: 28693241
Nat Immunol. 2002 Sep;3(9):867-74
pubmed: 12154358
Front Immunol. 2019 May 07;10:909
pubmed: 31134055
J Immunol. 2008 May 1;180(9):6018-26
pubmed: 18424722
Drug Des Devel Ther. 2021 May 27;15:2269-2287
pubmed: 34079226
Mol Ther Oncolytics. 2016 Dec 14;3:16031
pubmed: 28035331
Br J Haematol. 2013 Sep;162(6):842-5
pubmed: 23772929
Cancers (Basel). 2021 Feb 08;13(4):
pubmed: 33567530
Clin Orthop Relat Res. 1991 Jan;(262):3-11
pubmed: 1984929
Biomed Pharmacother. 2020 Apr;124:109821
pubmed: 31962285
Br J Cancer. 2019 Nov;121(10):837-845
pubmed: 31570753
Mol Ther Oncolytics. 2019 May 21;14:139-148
pubmed: 31211244
Oncoimmunology. 2018 Aug 27;7(11):e1509819
pubmed: 30377572
Clin Cancer Res. 2019 Dec 1;25(23):7126-7138
pubmed: 31484667
Viruses. 2018 Aug 26;10(9):
pubmed: 30149659
Oncotarget. 2017 Apr 11;8(15):24932-24948
pubmed: 28212561
J Transl Med. 2022 Nov 3;20(1):505
pubmed: 36329529
Biochem Biophys Res Commun. 2014 Nov 7;454(1):239-44
pubmed: 25451248
Nat Med. 2007 Sep;13(9):1050-9
pubmed: 17704786
Cytotherapy. 2008;10(2):212-9
pubmed: 18368600
EMBO Mol Med. 2020 Jun 8;12(6):e10979
pubmed: 32419365
Trends Immunol. 2018 Mar;39(3):209-221
pubmed: 29275092
Front Immunol. 2022 Oct 24;13:992232
pubmed: 36353643
Leuk Lymphoma. 2022 Jun;63(6):1407-1417
pubmed: 35133221
Front Immunol. 2018 Dec 03;9:2804
pubmed: 30559743
Front Pharmacol. 2022 Dec 01;13:1048978
pubmed: 36532743
Front Immunol. 2019 Nov 29;10:2806
pubmed: 31849980
J Leukoc Biol. 2005 Mar;77(3):361-8
pubmed: 15569694
Front Immunol. 2017 Sep 13;8:1134
pubmed: 28955344
Cancer Immunol Immunother. 2012 Nov;61(11):1989-2002
pubmed: 22527248
Front Oncol. 2019 Aug 27;9:811
pubmed: 31508370
Front Oncol. 2019 Jul 12;9:564
pubmed: 31355131
Exp Hematol Oncol. 2022 Jan 24;11(1):3
pubmed: 35074008
EBioMedicine. 2016 Jul;9:31-36
pubmed: 27407036
Mol Ther. 2007 Sep;15(9):1686-93
pubmed: 17579581
Int J Nanomedicine. 2022 Sep 07;17:3989-4008
pubmed: 36105615
J Clin Invest. 2018 Feb 1;128(2):644-654
pubmed: 29337311
Biomed Pharmacother. 2023 May;161:114503
pubmed: 36921539
Cancer Gene Ther. 2009 Mar;16(3):266-78
pubmed: 18846115
Cancer Cell Int. 2023 May 8;23(1):86
pubmed: 37158883
BMC Cancer. 2020 Jul 13;20(1):647
pubmed: 32660440
J Immunol. 2006 Jan 1;176(1):157-64
pubmed: 16365406
Cell Immunol. 2019 Apr;338:1-8
pubmed: 30850088
Glob Adv Health Med. 2012 Mar;1(1):92-100
pubmed: 24278806
PLoS One. 2016 Sep 06;11(9):e0161820
pubmed: 27598655
J Immunol. 2010 May 1;184(9):5360-7
pubmed: 20308630
Biomed Pharmacother. 2018 May;101:938-944
pubmed: 29635903
Sci Signal. 2017 Nov 21;10(506):
pubmed: 29162744
Cancer Res. 2019 Apr 1;79(7):1493-1506
pubmed: 30679180
J Transl Genet Genom. 2021;5:304-322
pubmed: 34888493
Front Immunol. 2022 May 23;13:886546
pubmed: 35677038
Leukemia. 2014 Apr;28(4):917-27
pubmed: 24067492
BMC Genomics. 2009 Jul 07;10:301
pubmed: 19583830
Front Oncol. 2021 Aug 23;11:728018
pubmed: 34497771
J Exp Med. 1999 Oct 18;190(8):1175-82
pubmed: 10523615
Cancer Control. 2023 Jan-Dec;30:10732748231159706
pubmed: 36826231
Oncoimmunology. 2019 Apr 7;8(7):1591875
pubmed: 31143509
Biomed Res Int. 2019 Jun 23;2019:8980506
pubmed: 31341910
J Transl Med. 2023 Mar 2;21(1):162
pubmed: 36864446
Cells. 2022 Aug 14;11(16):
pubmed: 36010596
Cancer Sci. 2019 Jan;110(1):256-268
pubmed: 30460757
Trends Cancer. 2021 Jun;7(6):557-572
pubmed: 33446447
Cells. 2022 May 16;11(10):
pubmed: 35626689
Blood. 2002 Jun 15;99(12):4525-30
pubmed: 12036884
Cancer Cell. 2017 Aug 14;32(2):135-154
pubmed: 28810142
Ir J Med Sci. 2021 Feb;190(1):41-57
pubmed: 32607912
J Immunother Cancer. 2020 Mar;8(1):
pubmed: 32217765
Nat Rev Clin Oncol. 2023 Jun;20(6):359-371
pubmed: 37055515
Clin Rheumatol. 2022 Oct;41(10):2929-2938
pubmed: 35635651
Immunotherapy. 2014;6(6):755-74
pubmed: 25186605
BJU Int. 2009 Jun;103(12):1714-20
pubmed: 19154459
Sci China Life Sci. 2019 May;62(5):633-639
pubmed: 30796720
Altern Ther Health Med. 1999 May;5(3):42-7
pubmed: 10234867
Cancer Discov. 2022 Jan;12(1):31-46
pubmed: 35022204
Int Immunopharmacol. 2018 Dec;65:148-158
pubmed: 30316073
Oncoimmunology. 2020 Jan 9;9(1):1703449
pubmed: 32002302
Cell Mol Immunol. 2023 May;20(5):432-447
pubmed: 36949244
J Biol Chem. 1996 Jan 5;271(1):21-4
pubmed: 8550562
Nat Commun. 2018 Nov 27;9(1):5006
pubmed: 30479334
Int J Mol Med. 2016 Oct;38(4):1021-9
pubmed: 27599781
Cell Death Dis. 2018 Oct 23;9(11):1086
pubmed: 30352991
Oncol Rep. 2017 Jan;37(1):368-378
pubmed: 27878284
Life Sci. 2021 Feb 15;267:118953
pubmed: 33359746
Scand J Immunol. 2004 Jan;59(1):50-7
pubmed: 14723621
Front Immunol. 2022 May 16;13:896228
pubmed: 35651603
Annu Rev Pharmacol Toxicol. 2020 Jan 6;60:457-476
pubmed: 31479618
Immunotherapy. 2018 Aug;10(11):935-949
pubmed: 30149762
J Clin Oncol. 2023 Jan 20;41(3):568-578
pubmed: 35960908
Peptides. 2021 Dec;146:170644
pubmed: 34464592
Comp Immunol Microbiol Infect Dis. 1985;8(2):171-85
pubmed: 3910342
Nat Rev Drug Discov. 2022 Nov;21(11):799-820
pubmed: 35974096
J Cell Biochem. 2017 Aug;118(8):1994-1999
pubmed: 28135008
Cancer Immunol Res. 2015 Jun;3(6):678-88
pubmed: 25678582
Med. 2022 Aug 12;3(8):538-564
pubmed: 35963235
Oncol Lett. 2016 Mar;11(3):2169-2175
pubmed: 26998143
Clin Cancer Res. 2022 Sep 15;28(18):3917-3928
pubmed: 35594163
Cell Immunol. 2022 Apr;374:104511
pubmed: 35381435
Front Immunol. 2021 Dec 07;12:743890
pubmed: 34950134
J Immunother Cancer. 2020 Apr;8(1):
pubmed: 32241808
J Immunol Res. 2017;2017:5737159
pubmed: 29075649
BMC Cancer. 2018 Jan 3;18(1):13
pubmed: 29298674
Expert Rev Anti Infect Ther. 2003 Aug;1(2):319-35
pubmed: 15482127
Immunohorizons. 2021 Jul 21;5(7):568-580
pubmed: 34290111
Int J Dermatol. 2002 May;41 Suppl 1:3-6
pubmed: 12087815
EXCLI J. 2023 Jan 13;22:131-145
pubmed: 36998710
Immunity. 2017 Feb 21;46(2):261-272
pubmed: 28228282
J Biol Chem. 1993 Apr 25;268(12):8808-14
pubmed: 8473325
Anticancer Agents Med Chem. 2015;15(4):433-52
pubmed: 25506727
CA Cancer J Clin. 2020 Mar;70(2):86-104
pubmed: 31944278
Cancer Cell Int. 2022 Apr 29;22(1):168
pubmed: 35488303
PeerJ. 2019 Sep 27;7:e7759
pubmed: 31579619
Int J Mol Sci. 2018 Aug 11;19(8):
pubmed: 30103488
Pharmacol Ther. 1994;64(3):529-64
pubmed: 7724661